Tempus AI Shares Pull Back Monday After FDA Approval for Pulmonary Hypertension Detection Tool

Tempus AI Inc shares fell on Monday, pulling back from a roughly 20% gain over the past week.

Personals Transaction Draws Attention

The stock's recent gains were driven by Phase III INTerpath-001 trial results from Merck & Co. Inc. and Moderna Inc., involving data on intismeran autogene combined with Keytruda for advanced melanoma.

These data put the company's $1.5 billion Personals Inc. deal in the spotlight.

Moderna uses Personals' sequencing platform to analyze tumor tissue and identify specific neoantigens needed to manufacture personalized doses.

Tempus AI Receives FDA Clearance for Pulmonary Hypertension Detection Tool

On Monday, Tempus received FDA 510(k) clearance for ECG-PH, an AI product designed to detect signs of pulmonary hypertension from standard electrocardiograms.

The clearance adds pulmonary hypertension to the company's FDA-cleared AI products, alongside atrial fibrillation and low ejection fraction.

Analyst Consensus and Recent Actions

The stock carries a Hold rating with an average price target of $61.27. Recent analyst actions include:

BTIG: Buy

Piper Sandler: Neutral

BTIG: Buy

Top ETFs Holding Tempus AI

ARK Innovation ETF: Weight 4.94%

ARK Genomic Revolution ETF: Weight 6.86%

WisdomTree BioRevolution Fund: Weight 2.52%

Tempus AI Momentum Ranking vs. Market

Here is Tempus AI's Edge scorecard, highlighting its strengths and weaknesses relative to the broader market:

Momentum: Bullish—despite today's sharp pullback, the stock continues to behave as a momentum name.

Conclusion: Tempus AI's Edge signals reveal a momentum-driven story, with the scorecard emphasizing trend strength over fundamentals.

For longer-term traders, this typically means risk management around support/resistance matters more than trying to "average down" on volatile days.

TEM price action: As of Monday's data release, Tempus AI stock was down 6.78% to $67.76.